Hemophilia drug study falls short: only 3 patients enrolled before termination
NCT ID NCT06530030
First seen Jan 29, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study aimed to see if a medicine called efanesoctocog alfa (Altuviiio) helps people with moderate or severe hemophilia A reach their personal goals and be more active. It planned to enroll 35 people aged 12 to 50 who were starting this preventive treatment. However, the study was stopped early after only 3 people joined, so no meaningful results were collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bleeding and Clotting Disorders Institute
Peoria, Illinois, 61614, United States
Conditions
Explore the condition pages connected to this study.